{
  "id": "63f042e2f36125a426000022",
  "type": "summary",
  "question": "What is the mechanisms of action of Gilteritinib?",
  "ideal_answer": "The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34350585",
    "http://www.ncbi.nlm.nih.gov/pubmed/35625776",
    "http://www.ncbi.nlm.nih.gov/pubmed/35637252"
  ],
  "snippets": [
    {
      "text": "Many of the hopeful predictions outlined in our AML review of 2018 are now therapeutic realities: gemtuzumab ozogamicin, venetoclax, FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib), CPX-351, glasdegib, oral decitabine, and oral azacitidine. Others may soon be (quizartinib, APR246 magrolimab, menin inhibitors). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34350585",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637252",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similarly high rates of composite complete remission (CRc) were observed in patients who received a FLT3 TKI before gilteritinib (CHRYSALIS, 42%; ADMIRAL, 52%) and those without prior FLT3 TKI therapy (CHRYSALIS, 43%; ADMIRAL, 55%).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637252",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic cells (blasts) with FLT3 mutations after gilteritinib (GILT, a 2nd generation tyrosine kinase inhibitor (TKI)) treatment, we performed proteomic screening of cytokine release and in vitro/ex vivo studies to investigate their associated signaling pathways and transcriptional regulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625776",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}